Nuvectis Pharma (NVCT) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

Management experience and track record

• Leadership team has over 25 years of industry experience and prior success in drug approvals at multiple companies.

• Previous drugs developed by the team addressed severe unmet needs in small oncology patient populations.

Pipeline overview and development status

• Two main oncology drug candidates: NXP 800 (phase 1B) and NXP 900 (phase 1A, nearing phase 1B).

• NXP 800 targets ARID1A-mutated ovarian cancer and cholangiocarcinoma, with Mayo Clinic running the latter study.

• NXP 900 is a selective SRC inhibitor, showing promising preclinical and early clinical results.

Clinical data and strategy

• NXP 800 showed initial efficacy but dose adjustments were needed due to thrombocytopenia; new dosing regimens are being tested with updates expected in two months.

• NXP 900 demonstrated high potency and selectivity, achieving up to 90% SRC inhibition at higher doses without major safety issues.

• Phase 1B for NXP 900 will focus on YES1 overexpression and relevant mutations, with combination arms planned for patients resistant to EGFR and ALK inhibitors.